RxDoctor Payments DataLook up a doctor →

Joseph Kremer, MD

Nephrology · Cincinnati, OHNPI 1093783177

Payments from drug & device makers

$28,943in general payments, 2019–2025

Across 611 payments — averaging $47.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Calliditas Therapeutics US Inc.$11K
  • Bayer$6K
  • AstraZeneca$2K
  • Vifor Pharma, Inc.$1K
  • Mallinckrodt Hospital Products Inc.$1K
  • Amgen$824
  • plus $7K from 32 others

What the payments were for

  • Consulting fees$12,74544%
  • Speaking & faculty fees$2001%
  • Travel & lodging$8743%
  • Food & beverage$14,60850%
  • Education$5162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,943 in reported general payments places this provider in the 85th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$172,620
Medicare patients
380
Services billed
1,867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NulojixBelatacept23$45,516
FarxigaDapagliflozin Propanediol33$29,043
VeltassaPatiromer Calcium Sorbitex16$21,283
Sevelamer Carbonate38$9,958
Cinacalcet Hcl28$8,765
AuryxiaFerric Citrate11$7,348
Tacrolimus49$7,251
Mycophenolate Mofetil28$3,772
Losartan Potassium283$2,800
Nifedipine ErNifedipine85$2,320
Metoprolol Succinate152$1,922
Eplerenone11$1,820
Potassium Citrate ErPotassium Citrate14$1,763
Amlodipine Besylate239$1,610
Torsemide72$1,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,915$29,04333 claims
Akebia Therapeutics IncAuryxia$441$7,34811 claims
ANI Pharmaceuticals, Inc.Valsartan$78$48818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 450 nephrology providers in Ohio.

Other nephrology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →